The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
The cost of health care for children and adults with sickle cell disease
Open accessAbstract
Although sickle cell disease (SCD) is marked by high utilization of medical resources, the full cost of care for patients with SCD, including care not directly related to SCD, is unknown. The purpose of this study was to estimate the total cost of medical care for a population of children and adults with SCD. We used data from individuals diagnosed with SCD enrolled in the Florida Medicaid program during 2001–2005 to estimate total, SCD‐related, and non‐SCD‐related cost per patient‐month based on patient age at the time of health care use. Across the 4,294 patient samples, total health care costs generally rose with age, from $892 to $2,562 per patient‐month in the 0–9‐ and 50–64‐year age groups, respectively. Average cost per patient‐month was $1,389. Overall, 51.8% of care was directly related to SCD, the majority of which (80.5%) was associated with inpatient hospitalizations. Notably, non‐SCD‐related costs were substantially higher than those reported for the general US population. These results suggest a discounted (3% discount rate) lifetime cost of care averaging $460,151 per patient with SCD. Interventions designed to prevent SCD complications and avoid hospitalizations may reduce the significant economic burden of the disease. Am. J. Hematol. 2009. © 2009 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320 · cited 2×
“Lifetime costs then were estimated by summing annualized costs through age 44, the approximate median survival for SCD patients [10].”
BackgroundMethodBegley, C. E., Famulari, M., Annegers, J. F., Lairson, D. R., Reynolds, T. F., Coan, S., Dubinsky, S., Newmark, M. E., Leibson, C., So, E. L., et al. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb00166.x · Cited by 599
The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States
Schackman, B. R., Gebo, K. A., Walensky, R. P., Losina, E., Muccio, T., Sax, P. E., Weinstein, M. C., Seage, G. R., Moore, R. D., & Freedberg, K. A. (2006) · Medical Care · doi:10.1097/01.mlr.0000228021.89490.2a · Cited by 410
Trends in the cost of illness for asthma in the United States, 1985-1994
Weiss, K. B., Sullivan, S. D., & Lyttle, C. S. (2000) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2000.109426 · Cited by 366
Lifetime Medical Costs of Obesity: Prevention No Cure for Increasing Health Expenditure
van Baal, P. H. M., Polder, J. J., de Wit, G. A., Hoogenveen, R. T., Feenstra, T. L., Boshuizen, H. C., Engelfriet, P. M., & Brouwer, W. B. F. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050029 · Cited by 270
The Management of Sickle Cell Disease
Telfair, J. (2002) · Cited by 241
Sickle Cell Anaemia: Progress in Pathogenesis and Treatment
Ballas, S. K. (2002) · Drugs · doi:10.2165/00003495-200262080-00003 · Cited by 181
Hydroxyurea and sickle cell anemia: effect on quality of life
Ballas, S. K., Barton, F. B., Waclawiw, M. A., Swerdlow, P., Eckman, J. R., Pegelow, C. H., Koshy, M., Barton, B. A., & Bonds, D. R. (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-59 · Cited by 166
Medical care utilization and mortality in sickle cell disease: A population-based study
Shankar, S. M., Arbogast, P. G., Mitchel, E. F., Cooper, W. O., Wang, W. C., & Griffin, M. R. (2005) · American Journal of Hematology · doi:10.1002/ajh.20485 · Cited by 150
Designing and Conducting Cost-effectiveness Analyses in Medicine and Health Care
(2002) · International Journal of Health Care Quality Assurance · doi:10.1108/ijhcqa.2002.06215dae.003 · Cited by 128
Lanzkron, S., Haywood, C., Segal, J. B., & Dover, G. J. (2006) · American Journal of Hematology · doi:10.1002/ajh.20703 · Cited by 122
Cost-effectiveness of hydroxyurea in sickle cell anemia
Moore, R. D., Charache, S., Terrin, M. L., Barton, F. B., & Ballas, S. K. (2000) · American Journal of Hematology · Cited by 96
Cost of hospitalizations associated with sickle cell disease in the United States.
Davis, H., Moore, R. M., & Gergen, P. J. (1997) · Europe PMC (PubMed Central) · Cited by 87
Shatin, D., Levin, R. A., Ireys, H. T., & Haller, V. (1998) · PEDIATRICS · doi:10.1542/peds.102.4.e44 · Cited by 87
Financial analysis of chronic transfusion for stroke prevention in sickle cell disease
Wayne, A. S., Schoenike, S., & Pegelow, C. H. (2000) · Blood · doi:10.1182/blood.v96.7.2369 · Cited by 72
Inpatient Health Care Use Among Adult Survivors of Chronic Childhood Illnesses in the United States
Okumura, M. J., Campbell, A., Nasr, S. Z., & Davis, M. M. (2006) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.160.10.1054 · Cited by 61
Nietert, P. J., Silverstein, M. D., & Abboud, M. R. (2002) · PharmacoEconomics · doi:10.2165/00019053-200220060-00001 · Cited by 59
Delea, T. E., Hagiwara, M., Thomas, S. K., et al. (2007) · American Journal of Hematology · doi:10.1002/ajh.21049 · Cited by 45
Grosse, S. D., Olney, R. S., & Baily, M. A. (2005) · Applied Health Economics and Health Policy · doi:10.2165/00148365-200504040-00006 · Cited by 44
The Costs of Children With Sickle Cell Anemia
Bilenker, J. H., Weller, W. E., Shaffer, T., Dover, G. J., & Anderson, G. F. (1998) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-199811000-00003 · Cited by 39
Costs, Charges, and Reimbursements for Persons With Sickle Cell Disease
Nietert, P. J., Abboud, M. R., Zoller, J. S., & Silverstein, M. D. (1999) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-199909000-00010 · Cited by 31
Karnon, J. D., Zeuner, D., Ades, A. E., Efimba, W., Brown, J., & Yardumian, A. (2000) · Journal of Public Health · doi:10.1093/pubmed/22.4.500 · Cited by 21
Children With Sickle Cell Disease and Human Immunodeficiency Virus-1 Infection
Kourtis, A. P., Bansil, P., Johnson, C. H., Meikle, S., Posner, S. F., & Jamieson, D. J. (2007) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000259953.79654.d0 · Cited by 16
Have Medicaid Reimbursements Been a Credible Measure of the Cost of Pediatric Care?
Broyles, R. S., Tyson, J. E., & Swint, J. M. (1997) · PEDIATRICS · doi:10.1542/peds.99.3.e8 · Cited by 4
Cited by
Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Piel, F. B., Steinberg, M. H., & Rees, D. C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1510865 · Cited by 1,488
Population Estimates of Sickle Cell Disease in the U.S.
Hassell, K. L. (2010) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2009.12.022 · Cited by 1,211
Thomson, A. M., McHugh, T. A., Oron, A. P., Teply, C., Lonberg, N., Vilchis Tella, V., Wilner, L. B., Fuller, K., Hagins, H., Aboagye, R. G., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00118-7 · Cited by 747
Piel, F. B., Steinberg, M., & Rees, D. C. (2016) · Spiral (Imperial College London) · doi:10.1056/nejmc1706325#sa6 · Cited by 659
Metadata
- Authors
- Kauf, T. L., Coates, T. D., Huazhi, L., Mody‐Patel, N., & Hartzema, A. G.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2009-04-08
- Volume
- 84
- Issue
- 6
- Pages
- 323-327
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2037439664
- Cited by
- 388
- References
- 25
- FWCI
- 5.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.